Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MMP8 | P22894 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 4/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA7 | P43166 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11025934 | 0.89 | ALDH1A1 (0.55) | LMNAL3MBTL1SLC1A1ALDH1A1CA1 | |
| SCHEMBL31532269 | 0.86 | ALDH1A1 (0.47) | L3MBTL1SLC1A1ALDH1A1CA1CA2 | |
| SCHEMBL31532270 | 0.86 | ALDH1A1 (0.47) | L3MBTL1SLC1A1ALDH1A1CA1CA2 | |
| SCHEMBL17783287 | 0.84 | MMP8 (0.55) | LMNAL3MBTL1SLC1A1ALDH1A1MMP8 | |
| SCHEMBL392233 | 0.83 | LMNA (0.54) | LMNAL3MBTL1SLC1A1ALDH1A1MMP8 | |
| SCHEMBL1785822 | 0.83 | CA1 (0.50) | LMNAL3MBTL1SLC1A1ALDH1A1MMP8 | |
| SCHEMBL1785824 | 0.83 | CA1 (0.50) | LMNAL3MBTL1SLC1A1ALDH1A1MMP8 | |
| SCHEMBL27846599 | 0.82 | PPARA (0.53) | L3MBTL1SLC1A1ALDH1A1CA1CA2 | |
| SCHEMBL809052 | 0.82 | SLC1A1 (0.55) | SLC1A1ALDH1A1CA1CA2CA7 | |
| SCHEMBL13198428 | 0.81 | SLC1A1 (0.56) | LMNAL3MBTL1SLC1A1ALDH1A1MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1588998-B1 | A process for the preparation of 2-chloro-3-(phenylmethoxy)propionic acid potassium salt | BRACCO IMAGING SPA (IT) | 2011-11-30 | — | — | EP | disclosed |
| EP-1588998-A1 | A process for the preparation of 2-chloro-3-(phenylmethoxy)propionic acid potassium salt | Bracco Imaging S.p.A. (IT) | 2005-10-26 | — | — | EP | disclosed |
| EP-1272493-B1 | A PROCESS FOR THE PREPARATION OF DECAHYDRO-2A,4A,6A,8A-TETRAAZACYCLOPENT[FG]ACENAPHTHYLENE AND FUNCTIONALIZED DERIVATIVES | BRACCO INT BV (NL) | 2005-10-19 | — | — | EP | disclosed |
| US-6897311-B2 | Process for the preparation of decahydro-2a,4a,6a,8a-tetraazacyclopent[fg]acenaphthylene and functionalized derivatives | BRACCO INTERNATIONAL BV (NL) | 2005-05-24 | — | — | US | disclosed |
| US-20040014974-A1 | Process for the preparation of decahydro-2a,4a,6a,8a-tetraazacyclopent[fg]acenaphthylene and functionalized derivatives | BRACCO INTERNATIONAL BV (NL) | 2004-01-22 | — | — | US | disclosed |
| EP-1272493-A2 | A PROCESS FOR THE PREPARATION OF DECAHYDRO-2A,4A,6A,8A-TETRAAZACYCLOPENT[FG]ACENAPHTHYLENE AND FUNCTIONALIZED DERIVATIVES | BRACCO INTERNATIONAL B.V. (NL) | 2003-01-08 | — | — | EP | disclosed |
| WO-2001079207-A2 | A PROCESS FOR THE PREPARATION OF DECAHYDRO-2A,4A,6A,8A-TETRAAZACYCLOPENT[FG]ACENAPHTHYLENE AND FUNCTIONALIZED DERIVATIVES | BRACCO INTERNATIONAL BV (NL) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014974-A1 | Process for the preparation of decahydro-2a,4a,6a,8a-tetraazacyclopent[fg]acenaphthylene and functionalized derivatives | CYP4F2, CYP4A11, CYP4F11 | LMNA 1390/4885L3MBTL1 4787/4885SLC1A1 4326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.